$SHMN The company has successfully demonstrated that ABBIE version 2, featuring an advanced dCas12a domain, can effectively modify cultured human cells, marking a critical advancement toward commercial-ready gene editing technology. https://finance.yahoo.com/news/sohm-achieves-...00066.html